On Friday, Shares of Regions Financial Corp (NYSE:RF), added 0.05% and closed at $10.33 in the last trading session. The last trading range of the stock ranges between $0.18 and $10.38. The company’s Market capitalization is $12.99 Billion with the total Outstanding Shares of 1.26 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $7.00 and reached to max level of $10.43. The annual ranking recognizes the most influential female leaders in the banking industry for their professional achievements, personal tenacity, and influence. Honorees will be recognized at an awards dinner and featured in the October 2016 issue of American Banker magazine.
“I want to personally congratulate Barb on this well-deserved honor. Her commitment to transparency, sound risk administration and focus on doing the right thing for our customers is evident to all who work with her,” said Matt Lusco, Chief Risk Officer for Regions Financial. “Just as importantly, Barb continuously looks for opportunities to recognize the contributions of Regions associates at all levels of the company and encourage the professional and personal growth of others, which positions our company well for the future.”
Godin joined Regions Financial in 2003 and has more than 40 years of experience in financial services. She was designated Chief Credit Officer in August 2010 and named to the Regions Operating Committee. Godin’s responsibilities include overseeing credit policy, credit administration and problem asset administration for Regions Bank. Godin has formerly been named one of American Banker magazine’s 25 Women to Watch.
Pfizer Inc. (NYSE:PFE), dropped -0.27% and closed at $33.56 in the last trading session. The last trading range of the stock ranges between $33.42 and $34.00. The company’s Market capitalization is $201.52 Billion with the total Outstanding Shares of 6.07 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $28.25 and reached to max level of $37.39. Pfizer Inc. (PFE) recently declared results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT® (sunitinib) as adjuvant therapy. The trial showed SUTENT extended disease-free survival (DFS) by more than one year as compared to placebo in patients who were at high risk for recurrence after surgical resection of renal cell carcinoma (RCC) (HR 0.761; P=0.030 [95% CI: 0.594-0.975]). These results will be presented recently during a Presidential Symposium (Abstract #LBA11_PR) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology being held in Copenhagen, Denmark. The results have also been published online by The New England Journal of Medicine.
Adjuvant therapies are treatments that can be given to reduce the likelihood of the cancer returning after initial treatment such as surgery.
“We are encouraged by the S-TRAC results because this is the first clinical trial to show raised disease-free survival in the adjuvant setting for RCC,” said lead investigator Alain Ravaud, M.D., Ph.D., CHU de Bordeaux Hôpital Saint André. “These data are promising for RCC patients as there are no effective treatments presently available in this setting.”
On the other hand share Idera Pharmaceuticals Inc (NASDAQ:IDRA), lost -8.26% and closed at $2.00 in the last trading session. The last trading range of the stock ranges between $1.81 and $2.10. The company’s Market capitalization is $202.76 million with the total Outstanding Shares of 121.38 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.19 and reached to max level of $4.42. Idera Pharmaceuticals, Inc. (IDRA) (“Idera” or the “Company”) recently declared the pricing of an underwritten public offering of 25,000,000 shares of common stock for a public offering price of $2.00 per share. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 3,750,000 shares of common stock. All of the shares in the offering are to be sold by Idera. The offering is expected to close on or about October 13, 2016, subject to customary closing conditions.
The gross proceeds to Idera from this offering are expected to be about $50.0 million, before underwriting discounts and commissions and offering expenses. Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs. J.P. Morgan and Goldman, Sachs & Co. are acting as joint bookrunning managers for the offering. Wedbush PacGrow and JMP Securities are acting as co-managers.